Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
Identifieur interne : 001032 ( PubMed/Corpus ); précédent : 001031; suivant : 001033Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
Auteurs : Nicolas Escriou ; Benoît Callendret ; Valérie Lorin ; Chantal Combredet ; Philippe Marianneau ; Michèle Février ; Frédéric TangySource :
- Virology [ 1096-0341 ] ; 2014.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), Genetic Vectors (genetics), Genetic Vectors (immunology), Humans, Male, Measles Vaccine (genetics), Measles Vaccine (immunology), Measles virus (genetics), Measles virus (immunology), Mice, SARS Virus (genetics), SARS Virus (immunology), SARS Virus (physiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus (administration & dosage), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Th1 Cells (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Spike Glycoprotein, Coronavirus, Viral Vaccines.
- chemical , genetics : Measles Vaccine, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Measles Vaccine, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- genetics : Genetic Vectors, Measles virus, SARS Virus.
- immunology : Genetic Vectors, Measles virus, SARS Virus, Severe Acute Respiratory Syndrome, Th1 Cells.
- physiology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Humans, Male, Mice.
Abstract
The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine.
DOI: 10.1016/j.virol.2014.01.002
PubMed: 24606680
Links to Exploration step
pubmed:24606680Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.</title><author><name sortKey="Escriou, Nicolas" sort="Escriou, Nicolas" uniqKey="Escriou N" first="Nicolas" last="Escriou">Nicolas Escriou</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France. Electronic address: nicolas.escriou@pasteur.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Callendret, Benoit" sort="Callendret, Benoit" uniqKey="Callendret B" first="Benoît" last="Callendret">Benoît Callendret</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lorin, Valerie" sort="Lorin, Valerie" uniqKey="Lorin V" first="Valérie" last="Lorin">Valérie Lorin</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Combredet, Chantal" sort="Combredet, Chantal" uniqKey="Combredet C" first="Chantal" last="Combredet">Chantal Combredet</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Marianneau, Philippe" sort="Marianneau, Philippe" uniqKey="Marianneau P" first="Philippe" last="Marianneau">Philippe Marianneau</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fevrier, Michele" sort="Fevrier, Michele" uniqKey="Fevrier M" first="Michèle" last="Février">Michèle Février</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Tangy, Frederic" sort="Tangy, Frederic" uniqKey="Tangy F" first="Frédéric" last="Tangy">Frédéric Tangy</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France. Electronic address: frederic.tangy@pasteur.fr.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24606680</idno><idno type="pmid">24606680</idno><idno type="doi">10.1016/j.virol.2014.01.002</idno><idno type="wicri:Area/PubMed/Corpus">001032</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001032</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.</title><author><name sortKey="Escriou, Nicolas" sort="Escriou, Nicolas" uniqKey="Escriou N" first="Nicolas" last="Escriou">Nicolas Escriou</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France. Electronic address: nicolas.escriou@pasteur.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Callendret, Benoit" sort="Callendret, Benoit" uniqKey="Callendret B" first="Benoît" last="Callendret">Benoît Callendret</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lorin, Valerie" sort="Lorin, Valerie" uniqKey="Lorin V" first="Valérie" last="Lorin">Valérie Lorin</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Combredet, Chantal" sort="Combredet, Chantal" uniqKey="Combredet C" first="Chantal" last="Combredet">Chantal Combredet</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Marianneau, Philippe" sort="Marianneau, Philippe" uniqKey="Marianneau P" first="Philippe" last="Marianneau">Philippe Marianneau</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fevrier, Michele" sort="Fevrier, Michele" uniqKey="Fevrier M" first="Michèle" last="Février">Michèle Février</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Tangy, Frederic" sort="Tangy, Frederic" uniqKey="Tangy F" first="Frédéric" last="Tangy">Frédéric Tangy</name><affiliation><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France. Electronic address: frederic.tangy@pasteur.fr.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Virology</title><idno type="eISSN">1096-0341</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (immunology)</term><term>Antibodies, Viral (immunology)</term><term>Genetic Vectors (genetics)</term><term>Genetic Vectors (immunology)</term><term>Humans</term><term>Male</term><term>Measles Vaccine (genetics)</term><term>Measles Vaccine (immunology)</term><term>Measles virus (genetics)</term><term>Measles virus (immunology)</term><term>Mice</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus (administration & dosage)</term><term>Spike Glycoprotein, Coronavirus (genetics)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term><term>Th1 Cells (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Measles Vaccine</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Measles Vaccine</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Genetic Vectors</term><term>Measles virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Genetic Vectors</term><term>Measles virus</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Th1 Cells</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Male</term><term>Mice</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24606680</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN><JournalIssue CitedMedium="Internet"><Volume>452-453</Volume><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Virology</Title><ISOAbbreviation>Virology</ISOAbbreviation></Journal><ArticleTitle>Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.</ArticleTitle><Pagination><MedlinePgn>32-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2014.01.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0042-6822(14)00005-1</ELocationID><Abstract><AbstractText>The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine. </AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Escriou</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France. Electronic address: nicolas.escriou@pasteur.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callendret</LastName><ForeName>Benoît</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorin</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combredet</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marianneau</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Février</LastName><ForeName>Michèle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangy</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France. Electronic address: frederic.tangy@pasteur.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Virology</MedlineTA><NlmUniqueID>0110674</NlmUniqueID><ISSNLinking>0042-6822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008458">Measles Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008458" MajorTopicYN="N">Measles Vaccine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008459" MajorTopicYN="N">Measles virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Measles vaccine</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome</Keyword><Keyword MajorTopicYN="N">Spike glycoprotein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>11</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>01</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24606680</ArticleId><ArticleId IdType="pii">S0042-6822(14)00005-1</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2014.01.002</ArticleId><ArticleId IdType="pmc">PMC7111909</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2006 Apr 24;24(17):3624-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16497416</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2011 Jul;85(14):7095-107</Citation><ArticleIdList><ArticleId IdType="pubmed">21543501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Sep 15;190(6):1119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15319862</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 Jun;80(12):5757-67</Citation><ArticleIdList><ArticleId IdType="pubmed">16731915</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pediatr Infect Dis J. 2000 Dec;19(12):1211-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11144388</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2011 Mar;18(3):355-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21228137</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Sep 30;340(2):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2012;7(4):e35421</Citation><ArticleIdList><ArticleId IdType="pubmed">22536382</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):45-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17416434</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(19):10328-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15367599</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2005 Jan 15;191(2):207-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15609230</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2007 Jul 5;363(2):288-302</Citation><ArticleIdList><ArticleId IdType="pubmed">17331558</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1211-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22983013</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2009 May 25;388(1):191-203</Citation><ArticleIdList><ArticleId IdType="pubmed">19345390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2012;7(11):e50397</Citation><ArticleIdList><ArticleId IdType="pubmed">23226275</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1997 Jan 20;227(2):314-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9018130</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Aug;11(8):1312-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16110580</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 2004 May;42(5):2043-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15131168</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Nov;77(21):11546-54</Citation><ArticleIdList><ArticleId IdType="pubmed">14557640</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):20-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17499378</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drugs Today (Barc). 2008 Jan;44(1):63-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18301805</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2005 Nov;56(5):919-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16183666</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 May 2;23(24):3202-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15837221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Jun;87(12):6551-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23576515</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2011 Dec;85(23):12201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21937658</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Dec 4;58(47):1321-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19959985</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12111-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22773820</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viral Immunol. 2005;18(2):317-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16035943</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>New Microbiol. 2012 Jan;35(1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">22378548</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2006 Mar 1;193(5):685-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Vaccines. 2009 Jul;8(7):887-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19538115</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Aug 12;31(36):3718-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23742993</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Jun;3(6):e177</Citation><ArticleIdList><ArticleId IdType="pubmed">16683867</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2012 Jul 15;206(2):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22551814</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2003 Jun 2;21(19-20):2580-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12744894</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Sep;72(9):7420-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9696838</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2010 Dec;84(24):12658-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20926566</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2011 Jun 1;203(11):1574-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21592986</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2011 Jan;85(1):217-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20980507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 Aug;80(16):7918-28</Citation><ArticleIdList><ArticleId IdType="pubmed">16873249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2001 Oct 1;184(7):817-26</Citation><ArticleIdList><ArticleId IdType="pubmed">11528592</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2010 Apr 08;6(4):e1000849</Citation><ArticleIdList><ArticleId IdType="pubmed">20386712</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2004 Mar 12;22(9-10):1214-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15003650</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Negl Trop Dis. 2007 Dec 12;1(3):e96</Citation><ArticleIdList><ArticleId IdType="pubmed">18160988</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2013 Aug 20;4(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">23963179</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Apr 10;334(2):160-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15780866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2002 Jun 21;20(21-22):2790-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12034106</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Sep;79(18):11892-900</Citation><ArticleIdList><ArticleId IdType="pubmed">16140765</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jan;78(1):146-57</Citation><ArticleIdList><ArticleId IdType="pubmed">14671096</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2005 Sep;128(1-2):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15885812</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Aug;82(15):7721-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18463152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1993 Aug;67(8):4822-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8392616</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2003 Jul 28;21(24):3398-405</Citation><ArticleIdList><ArticleId IdType="pubmed">12850348</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMJ. 2011 Jun 15;342:d3724</Citation><ArticleIdList><ArticleId IdType="pubmed">21677008</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2008 Apr 16;26(17):2164-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18346823</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11416-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15452265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Oct 25;341(2):215-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16099010</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001032 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001032 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24606680
|texte= Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24606680" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |